Speaker Spotlight: See Some of the Investor and Strategic Partner Panelists Joining us at RESI Philadelphia

18 Apr

By Karen Deyo, Investor Research Analyst, LSN

LSN is gearing up for our next RESI on June 3rd in Philadelphia. The conference will feature two RESI panel tracks, with panels designed to provide fundraising CEOs with advice on what investors and strategic partners are seeking, as well as tips on how to approach them. Panels will range from discussions by different types of investors, such as Corporate Venture Capital, Angels & Family Offices and Asia Corporates & Strategics, to those focused on particular areas, ranging from general topics such as Medical Device Investors and Early Stage Therapeutics to AI in Healthcare and Mental & Behavioral Health. Join us at RESI Philadelphia to hear the speakers below share their expertise.

Zishan Haroon, Julz Co., Aisa Therapeutics

Dr. Haroon brings over two decades of experience in venture, private equity, corporate/business development and academia (with direct transactional and operational exposure of 15+ years in China) to lead Julz, a US based fund focused in healthcare opportunities worldwide. Julz has offices in NC and Suzhou China to exploit the tremendous opportunity offered in healthcare in both US and China. The investment spans all facets from innovative drugs, devices to services such as hospitals and diagnostic labs.

Somjeet Dey, Otsuka Pharmaceuticals, Asia Therapeutics

Somjeet has been working with Otsuka’s Business Development department since 2013 and he presently leads the company’s business development operations in the US for drugs, devices and diagnostics. Somjeet believes in Otsuka’s “big venture” spirit and is committed to strategically building a product pipeline that would sharpen the company’s long-term competitive edge. Consequently, he engages regularly with academia, accelerators and VCs to explore growth opportunities for Otsuka. He played an active role in the buy-side due diligence and negotiations for Otsuka’s recent acquisitions of Neurovance, Inc. and Visterra, Inc. Before joining Otsuka, Somjeet developed and implemented technology solutions for financial institutions across Asia, Africa, Europe and North America. He received his MBA degree from The Ohio State University.

Sohaib Siddiqui, Kettlebeck Developments, Digital Health

Dr. Sohaib Siddiqui is a managing partner at Kettlebeck Ventures, which is a family office based in Toronto, Canada.  The company maintains a diverse portfolio of investments in land, tech and healthcare.  Sohaib leads the healthcare strategy which aims to conduct impact investing in life science.  As part of the company’s healthcare thesis, the group aims to advise early stage start-ups, help them network in the healthcare ecosystem and make strategic investments.

Sohaib has a Bachelor of Science in Biology from Queen’s University.  He also studied at the Royal College of Surgeons in Ireland where he has received degrees in Medicine, Surgery, Obstetrics and Gynecology. He loves working with start-ups in order to provide strategic capital and insight to tackle challenging problems in healthcare.

Richard Gordon, Inova Strategic Investments, Digital Health

Rick Gordon is an expert on technology investing, business strategy and early-stage venture development. He is a leader with more than 25 years’ experience in providing organizations with strategic growth.

Rick is a Director at Inova Health System’s Personalized Health Accelerator, the health system’s seed investment organization.

Rick formerly served as founding Managing Partner of MACH37, a cybersecurity market centric accelerator supported by a community of industry leaders. MACH37 invests in entrepreneurs and helps them develop into thriving cybersecurity companies. Rick was previously CEO of Tovaris, a specialized encryption software development company, and was also a technology investment banker at Bear, Stearns & Co.

Rick served as a submarine officer in the U.S. Navy. He received his MBA from The Darden School at the University of Virginia and his BS in Engineering with Merit from the U.S. Naval Academy.

Ronald Dorenbos, Takeda Pharmaceuticals – Materials & Innovation, Medical Device Investors

Ronald is Associate Director at Takeda’s Materials & Innovation team, a group that scouts for new technologies related to drug delivery and biomaterials. During his appointment at the Life Science division of PA Consulting Group, a British Consulting firm, Ronald led projects for some of the world’s top 10 pharmaceutical companies around strategy, commercialization and digital health. At his company BioFrontline he provides management, strategy and commercial advice to life science companies around the world. Ronald received MAs in Biotechnology and Molecular Biology and after obtaining a PhD in Pharmaceutical Biology spent six years at Harvard to study Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of developments in the field of Artificial Intelligence (AI) and regularly invited as speaker to present on topics related to pharma, healthcare and AI.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: